The release of amyloid precursor protein (APP) intracellular domain (AICD) may be triggered by extracellular cues through γ-secretase-dependent cleavage. AICD binds to Fe65, which may have a role in AICD-dependent signalling; however, the functional ligand has not been characterized. In this study, we have identified TAG1 as a functional ligand of APP. We found that, through an extracellular interaction with APP, TAG1 increased AICD release and triggered Fe65-dependent activity in a γ-secretasedependent manner. TAG1, APP and Fe65 colocalized in the neural stem cell niche of the fetal ventricular zone. Neural precursor cells from TAG1 -/-, APP -/-and TAG1 -/-;APP -/-mice had aberrantly enhanced neurogenesis, which was significantly reversed in TAG1 -/-mice by TAG1 or AICD but not by AICD mutated at the Fe65 binding site. Notably, TAG1 reduced normal neurogenesis in Fe65 +/+ mice. Abnormally enhanced neurogenesis also occurred in Fe65 -/-mice but could not be reversed by TAG1. These results describe a TAG1-APP signalling pathway that negatively modulates neurogenesis through Fe65.
The γ-secretase proteolytic complex cleaves a wide spectrum of type-1 transmembrane protein substrates, including Notch and APP, by regulated intramembrane proteolysis (RIP) to release their intracellular domains 1 . Ligand-binding to the substrate protein is one mechanism by which this cleavage is regulated. When a ligand binds to Notch, RIP stimulates the release of the intracellular domain of Notch (NICD), which interacts with the transcription factor CSL (CBF1, Suppressor of Hairless and Lag1; ref. 1). Similar transcriptional activity or regulation has been proposed for the intracellular domains cleaved from other γ-secretase substrates, including AICD, which is cleaved from APP 1 . It is therefore important to understand the physiological mechanisms regulating cleavage of AICD.
Glycophosphatidylinositol (GPI)-linked proteins are anchored to the outer leaflet of the plasma membrane and mediate the dynamic remodelling of membranes during cell-cell interactions. In the central nervous system (CNS), GPI-linked recognition molecules, such as TAG1, NB-3 and F3, have been implicated in key developmental events, including selective axonal fasciculation, neural cell adhesion and migration, and neurite outgrowth 2 . Recently, we identified F3 and its homologue NB-3 as functional ligands for the Notch receptor and we showed that their interaction with each other is involved in oligodendrocyte differentiation through activation of the transcriptional factor Deltex1 (refs 3, 4) . Given that RIP processing of APP is strikingly similar to that of the Notch receptor 5 , knowledge of the interaction between F3 and the Notch receptor has led us to ask whether members of the F3 family may act as APP ligands.
RESULTS

TAG1 and APP bind to each other
To investigate the potential interaction between APP and members of the F3 subfamily, cell adhesion assays were performed. When F3-transfected CHO (CHOF3) cells or non-transfected CHO cells were seeded onto culture dishes spotted with APP-Fc (recombinant APP extracellular domain in fusion with the Fc part of immunoglobulin), little adhesion was observed (Fig. 1a) . However, when CHO cells transfected with TAG1 (CHOTAG1), or TAX (the human homologue of TAG1; CHOTAX; data not shown), were seeded onto culture dishes spotted with APP-Fc, the cells readily adhered to the APP protein spots (Fig. 1a) . Adhesion could be blocked by pre-treating the cells with an anti-TAG1 antibody or the culture dishes with an anti-APP antibody (22C11; Fig. 1a ), indicating that the interaction of TAG1 with APP contributes to adhesion. In reciprocal adhesion assays, in which APPtransfected CHO (CHOAPP) cells were plated on culture dishes with TAG1-Fc protein spots, we observed similar adhesion of cells to the protein spots (Fig. 1a) . Cell adhesion was blocked by neutralization of coated TAG1 protein spots or cell-membrane-bound APP with their respective antibodies (Fig. 1a, b) . Likewise, control, non-transfected CHO cells did not adhere to the TAG1 protein spots (Fig. 1a, b) . To identify the APP-binding domains in TAX, GST fusion proteins of the six immunoglobulin (Ig) domains (TAXIg-GST) and four fibronectin type III (FNIII) repeats (TAXFNIII-GST) of TAX were used as coated protein substrates for CHOAPP cells. The cells bound to spots of both proteins (Fig. 1a) , indicating that APP has at least two binding sites located in the TAG1 Ig domains and FNIII repeats. Consistently, control, non-transfected CHO cells did not adhere to either of these two proteins or to GST alone (Fig. 1a) . and APP knockouts (APP -/-) confirmed the specificity of the antibody. Reciprocal assays used an anti-APP antibody (171610) or APP-Fc to capture the protein complex and anti-TAG1 antibodies to detect the binding partner. (d) GST Pull-down assay (GST-P) to analyse the interaction between TAX and APP. Mouse brain, CHOAPP and CHO cell lysates were precipitated using TAXFNIII-GST, TAXIg-GST and GST, and probed with an anti-APP antibody. Brain, CHOAPP and CHO inputs are shown in the right panel. (e) Brain lysates of wild-type mice were co-immunoprecipitated using antibodies against APLP1, APLP2, APP, phoshoAPP (Thr 668), TAG1 and non-immune IgG, and probed with antibodies against APLP1 and APLP2. Full scans of gels in c-e are shown in Supplementary Information, Fig. S6 .
Next, we performed immunoprecipitation and Fc or GST pull-down assays in adult mouse brains to confirm that TAG1 interacts with APP. The results showed that several antibodies against TAG1, including 1C12 (Fig. 1c) , 4D7 and TG3 ( Supplementary Information, Fig. S1a ), but not IgG or an anti-F3 antibody ( Supplementary Information, Fig. S1a ), could precipitate APP from wild-type mouse brains (Fig. 1c) . Conversely, an anti-APP antibody (171610) could precipitate TAG1 from wild-type brains (Fig. 1c) . Inputs (Fig. 1c) and immunoprecipitation controls ( Supplementary Information, Fig. S1b, c ) from the respective wild-type and knockout mouse brains confirmed the specificity of co-immunoprecipitation and the antibodies used. Consistent with the cell-adhesion results, APP-Fc precipitated TAG1 from mouse brains (Fig. 1c) and both TAXIg-GST and TAXFNIII-GST precipitated APP from mouse brains as well as from CHOAPP cells (Fig. 1d) . In contrast to antibodies against APP, those directed against phosphoAPP (Thr 668), TAG1 (1C12), amyloid precursor-like protein 1 (APLP1) and APLP2 and could not precipitate APLP1 or APLP2 from wild-type mouse brains (Fig. 1e ). These results demonstrate that APP and TAG1 bind to each other.
TAG1 and APP colocalize in the neurogenic ventricular zone and neural progenitor cells
We studied the localization of TAG1 and APP in embryonic day (E) 14 mouse brains by immunofluorescence labelling, using antibodies against TAG1 (AF1714) and APP (C7, Fig. 2a; 22C11, Fig. 2b ).
Immunofluorescence microscopy showed that APP or TAG1 were colocalized with nestin ( Fig. 2a) , a neural progenitor-cell marker, in the walls of the lateral ventricles of wild-type but neither in APP -/-nor TAG1 -/-mice ( Supplementary Information, Fig. S1d ). Double immunofluorescence labelling showed that APP and TAG1 were co-expressed in the lateral ventricle Results are mean ± s.e.m., n = 3-6, **P < 0.001. 
90%). (d).
Human AICD59 cDNAs were cloned into the pCDF1-MCS1-EF1-copGFP mammalian expression vector. HEK293 cells in 60-mm plates were transfected with AICD59 or empty vector and harvested 24 h after transfection. The cell lysate was subjected to western blotting using antibodies against c-terminal APP and γ-tubulin. (e, f) NPCs were isolated from TAG1 -/-and co-transfected with AICD59 and GFP in a pCDF1-MCS1-EF1-copGFP vector (AICD59) and empty vector containing only GFP (GFP) as a control. After differentiation, the cells were double-stained for TUJ1 and DAPI (e). White arrows indicate neurons infected with GFP or AICD59 and GFP and yellow arrows indicate non-neurons infected with GFP or AICD59 and GFP (e). The numbers of TUJ1-positive neurons infected with AICD59 and GFP (58.21 ± 2.21%) or GFP (69.06 ± 2.14%) were counted and normalized as a percentage of the total number of GFPpositive neurons (f). Bars are 100 μm. Results are mean ± s.e.m., n = 5, **P < 0.001. TAG1 are expressed by NPCs. Double-staining for APP (22C11) and TAG1 (TG3) also showed that these proteins are colocalized in NPCs (Fig. 2e) . Consistent with these observations, western blotting with anti-TAG1 (TG1) and anti-APP (22C11) antibodies detected TAG1 and APP bands, respectively, in both mouse brain and NPCs (Fig. 2f) . The interaction between TAG1 and APP was confirmed by immunoprecipitation in isolated NPCs using antibodies against APP (171610) and TAG1 (1C12) (Fig. 2g) , suggesting that the interaction between these two molecules may also occur in NPCs. These results demonstrate that both TAG1 and APP are expressed by NPCs in the neural stem-cell niche.
TAG1 and APP modulate neurogenesis
To assess the role of the TAG1-APP interaction in modulating neurogenesis, NPCs were isolated from E14 telencephalic ventricular walls of APP -/-( Fig. 3a) and TAG1 -/- (Fig. 3b) mice. APP null mice show increased mortality after birth. Adult APP null mice are usually smaller than wild-type mice but at E14 there are no observable gross phenotypic differences. TAG1 null mice show no gross phenotypic abnormalities, although the adult mice exhibit elevated expression of adenosine A1 receptors in the hippocampus and increased seizure susceptibility to convulsant stimuli 6 . Seven to eight days after in vitro differentiation, cells were double-stained for class III β-tubulin (TUJ1, green; Fig. 3a , b) or microtubule-associated protein 2 (MAP2; data not shown), two markers of differentiated neurons, and DAPI (blue; Fig. 3a, b) . Both TUJ1-and MAP2-positive cells were significantly increased in APP-and TAG1-knockout mice (Fig. 3a , b, respectively), compared with wild-type littermates. TUNEL assay showed that the number of apoptotic cells was not different between TAG1 -/-and TAG1 +/+ NPC cultures ( Supplementary  Information, Fig. S2a ). We also generated TAG1 -/-;APP -/-fetuses and found that this double knockout was usually developmentally lethal; few mice survived to birth but some fetuses were recovered at E14. Consistent with our observations in single knockout mice, TUJ1-positive cells were significantly increased in TAG1 -/-;APP -/-double-knockout mice, compared with wild-type littermates (Fig. 3c ). These results demonstrate that the interaction between TAG1 and APP may be involved in modulating neurogenesis during the early stages of CNS development.
TAG1 stimulates AICD release
We investigated whether TAG1 could regulate AICD release in an artificial luciferase reporter system 7 . In this system, the Gal4 DNA-binding domain of Saccharomyces cerevisiae was inserted into the intracellular tail of full-length APP at the cytoplasmic boundary of the transmembrane region 7 . Only after γ-secretase cleavage is the AICD-Gal4 element released to drive luciferase reporter activity by means of the Gal4 response element. This system measures release of AICD but does not demonstrate that AICD is involved in endogenous transcriptional activation. We introduced this reporter system, together with Fe65, into non-transfected CHO and CHOL1, CHOTAG1 or CHOTAX cells. A significant upregulation of the reporter activity was observed in both CHOTAG1 and CHOTAX cells but neither in the control nor CHOL1 cells ( Fig. 4a; Supplementary Information, Fig. S3a-c) . To confirm that the extracellular interaction between APP and TAG1 is essential for triggering AICD luciferase activity, we transfected a modified luciferase reporter system (C99), in which the extracellular domain of APP was deleted from the aforementioned APP-Gal4 construct, into CHOTAG1 cells ( Supplementary Information, Fig. S3a ). In these cells, reporter activity was no longer increased (Fig. 4a) . Moreover, two specific γ-secretase inhibitors, L-685,458 and DAPT, reduced the TAG1-triggered release of AICD in a concentration-dependent manner (Fig. 4b, c) . In contrast, TAG1 did not activate NICD-dependent, Hes1-mediated activity ( Supplementary Information, Fig. S3d ). These observations suggest that TAG1 triggers AICD release in a γ-secretase dependent manner.
To support the notion that TAG1 can trigger AICD release after binding with full-length APP, we investigated the AICD level by western blotting. CHOAPP cells were co-transfected with cDNAs of Fe65, presenilin-1 (PS1) and TAG1 or empty vector (plasmid pRC) as a control. Cell lysates were subjected to western blotting using antibodies against the C-terminal of APP (A8717), TAG1 (TG1) and γ-tubulin. Transfection with TAG1 cDNA, but not the empty vector, significantly increased AICD release in the CHOAPP cells (Fig. 4d , e) and this increase was blocked by a γ-secretase inhibitor, L-685,458 (5 μM; Fig. 4f ). The level of APP expression was not different between these two groups (Fig. 4e) . CHO cells were also co-transfected with cDNAs of APP-V5 (APP fused with the V5 epitope tag sequence derived from the P and V proteins of Simian virus 5), Fe65, BACE1 and TAG1 or pRC vector (Mock) as a control and total protein was analysed by western blotting with antibodies against TAG1 (TG1), V5 (R960-25) and γ-tubulin (Fig. 4g ). Western blotting with an anti-V5 antibody showed that TAG1 transfection increased AICD-V5 release in CHO cells compared with the mock transfection control (Fig. 4g) .
To ascertain whether TAG1 could also stimulate endogenous release of AICD, we transfected mouse embryonic fibroblasts (MEFs) with an empty pRC vector or with various concentrations of TAG1 cDNA. We observed a concentration-dependent increase in the production of endogenous AICD (Fig. 4h) . We also compared the effects of two concentrations of TAG1 protein on endogenous AICD production in MEFs. Again there was a concentration-dependent increase in the production of endogenous AICD in cells treated with TAG1 (Fig. 4i) . The effect of TAG1 on endogenous AICD production was further confirmed by investigation of AICD expression in E15 brains of TAG1
+/-and TAG1 -/-mouse embryos. There was a reduction in expression of endogenous AICD in the heterozygous and homozygous TAG1-null mouse brains that corresponded with the reduction in expression of TAG1 (Fig. 4j) . However, there was no change in NICD and Hes protein expression in TAG1-null mouse brains ( Supplementary Information, Fig. S3e ). In addition to AICD production, which requires γ-secretase cleavage, C-terminal fragment-(CTF) α and CTF-β were detected in the in vitro cell culture experiments. There was a marked preponderance of CTF-α over CTF-β but both CTF-α and CTF-β increased in response to TAG1 (Fig. 4d, h, i) , suggesting that, although α-secretase cleavage dominates, both α-and β-secretase cleavage increase in response to TAG1.
To further examine the notion that TAG1 is a functional ligand of APP, capable of triggering the release of AICD, we used the luciferase reporter system in cells isolated from TAG1 ;APP -/-NPCs were cultured as monolayers in culture dishes co-coated with TAG1-Fc, L1-Fc, F3-Fc or laminin. As expected, TAG1-Fc, but not F3-Fc, L1-Fc or laminin, strongly triggered reporter activity (Fig. 4k ), indicating that AICD had been released. A specific γ-secretase inhibitor (L-685,458) blocked the induction of AICD release by TAG1 in a concentration-dependent manner (Fig. 4l) , indicating that γ-secretase is involved in the TAG1 triggered RIP process in the TAG1 -/-;APP -/-double knockout fetal NPCs. Similarly to the observations in CHOTAG1 and CHOTAX cells (Fig. 4a) , these experiments demonstrate that AICD-dependent activity in the luciferase reporter system is also regulated by the interaction between TAG1 and APP in NPCs. Together, these results indicate that TAG1 may trigger AICD release by a γ-secretase-dependent mechanism.
AICD is necessary for the negative modulation of neurogenesis by the TAG1-APP signalling pathway To investigate the role of the TAG1-APP signalling pathway in neurogenesis, we treated TAG1 -/-and TAG1 -/-;APP -/-fetal NPCs with soluble TAG1 (70 nM and 140 nM) during differentiation. The cells were double-stained for TUJ1 and DAPI and the amount of staining was quantified. After TAG1 treatment, the number of TUJ1-positive cells was significantly decreased in fetal NPCs from TAG1-null mice, compared with the PBS-treated control group (Fig. 5a, b, c) . Similar treatment could not reverse the abnormally increased neurogenesis in TAG1 -/-;APP -/-double knockout mice (Fig. 5c ). Together these findings indicate that APP is a functional receptor of TAG1 that modulates neurogenesis. To test this idea, we transfected TAG1 -/-knockout fetal NPCs with AICD59, an intracellularly active fragment of APP released after TAG1-APP interaction, together with green fluorescent protein (GFP) in the same vector but under the control of a different promoter (Fig. 5d, e) . The number of TUJ1-positive cells in the AICD59 transfected group was significantly decreased, compared with the control group transfected with GFP alone ( Fig. 5f ; P < 0.001). Treatment with a γ-secretase inhibitor increased neurogenesis in wild-type NPCs ( Supplementary Information, Fig. S4a ; P < 0.001); however, a similar, but slightly less significant, effect was also observed in NPCs from APP-null mice ( Supplementary Information, Fig. S4b ; P < 0.05). To investigate whether AICD could induce apoptosis, we performed a TUNEL assay on the TAG1 -/-NPCs transfected with either AICD59 or empty vector (GFP) as a control. There was no difference in the number of apoptotic cells between these two group cells ( Supplementary  Information, Fig. S2b ), suggesting that AICD does not induce apoptosis in the transfected NPCs. These observations support the hypothesis that the TAG1-APP signalling pathway negatively regulates neurogenesis through AICD during early CNS development.
Fe65 is also expressed in the neurogenic ventricular zone and NPCs and negatively modulates neurogenesis
The mammalian Fe65 protein family consists of Fe65, Fe65L1 and Fe65L2. This class of scaffolding proteins has three structural domains, which include a WW domain (two tryptophans) and two phosphotyrosine-binding domains (PID1-PTB1 and PID2-PTB2) that mediate protein-protein interactions. All Fe65 protein family members bind to members of the APP protein family (APP, APLP1 and APLP2) through the C-terminal PID2-PTB2 domain 8 . It has been suggested that Fe65 has a role in AICD-dependent transcriptional activation 7 , but, unlike Fe65, the Fe65L1 and Fe65L2 interactions with APP do not activate APPdependent transcription 9, 10 . Therefore, we investigated whether Fe65 acts as a downstream element in the TAG1-APP signalling pathway regulating neurogenesis. We studied the localization of Fe65 expression in E14 mouse brains and in isolated NPCs from E14 mouse telencephalic ventricular walls by double immunofluorescence labelling, using antibodies against Fe65 and either nestin or Sox2. In the E14 mouse brain, immunofluorescence microscopy showed that Fe65 was colocalized with nestin ( Fig. 6a) in the ventricular walls. Similarly, Fe65 colocalized with Sox2 in NPCs (Fig. 6b) . Western blotting detected a Fe65 band in both NPCs and total mouse brain (Fig. 6c ). These results demonstrate that Fe65, like TAG1 and APP, is expressed by NPCs in the neural stem-cell niche. To determine the developmental expression of TAG1, APP and Fe65, fetal brain lysates from E10 to postnatal day (P) 0 mouse brains were analysed by western blotting with antibodies against TAG1 (TG1), APP (A8717), Fe65 (3H6) and γ-tubulin ( Supplementary Information,  Fig. S5 ). TAG1 and Fe65 were present from E12, whereas APP was detectable from E10. TAG1 was most strongly expressed from E16 to E18, but APP and Fe65 levels continued to increase to P0. Thus, all three proteins are present during fetal brain development, with APP switching on as cortical neurogenesis peaks at E14 to E15 (ref. Supplementary Information, Fig. S2c ;APP -/-mice, Fe65 deletion also leads to abnormal enhancement of neurogenesis.
Fe65 is a downstream element of TAG1-APP signalling during modulation of neurogenesis
Our observations imply that Fe65 may act as a downstream element in the TAG1-APP signalling pathway. To test this hypothesis, we introduced a luciferase reporter system in which Gal4 is fused to the N-terminal of Fe65 (ref. 12) into CHOTAG1 cells. When co-transfected with APP, but not with the empty vector used as a control, a significant upregulation of reporter activity was observed in CHOTAG1 cells (Fig. 7a) . Notably, co-transfection with an APP mutant (APP*) that abolishes Fe65 binding and transactivation (NPTY to NATA mutation 12 ) did not increase the TAG1-triggered, Fe65-dependent transcriptional activity (Fig. 7a) ; however, this activity was reduced by a specific γ-secretase inhibitor, DAPT (Fig. 7a) . We introduced this luciferase reporter system into CHO cells. When TAG1 cDNA, but neither TAG1 alone nor the empty vector control, was co-transfected with APP cDNA, but not the APP* mutant, a significant upregulation of reporter activity was observed, which could be reduced by DAPT (Fig. 7b) . To investigate whether both Fe65 and TAG1 could modulate intracellular release of AICD in wild-type fetal NPCs, these cells were transfected with the APP-Gal4 luciferase reporter system and Fe65, and were cultured as monolayers in culture dishes co-coated with TAG1-Fc and laminin. As expected, Fe65 increased the AICD-dependent reporter activity in the APP-Gal4-, Fe65-transfected NPCs, compared with those transfected with mock control or empty vector (Fig. 7c) . Consistently, after TAG1-Fc treatment, the AICDdependent reporter activity was markedly increased in the Fe65-transfected NPCs, compared with the non-treated group (Fig. 7c) . Thus, these results demonstrate that TAG1 regulates not only AICD-dependent, but also Fe65-dependent, activity in the luciferase reporter system in a γ-secretase dependent manner, suggesting that TAG1 stimulation of APP causes intracellular release of AICD and activation of Fe65.
Next, we investigated whether TAG1 could modulate neurogenesis in fetal NPCs isolated from Fe65 -/-mice. TAG1 protein was applied to trigger the TAG1-APP signalling pathway in fetal NPCs isolated from either Fe65 +/+ or Fe65 -/-mice. The number of TUJ1-positive cells was significantly decreased in the TAG1-treated NPCs from Fe65 +/+ mice, compared with the PBS-treated group (Fig. 7d, e) . However, TAG1 could not reverse the abnormal increase in neurogenesis in the Fe65 -/-mice (Fig. 7d, e) . To confirm that Fe65 has a role in the TAG1-APP-dependent modulation of neurogenesis, we transfected an AICD59 mutant (AICD59* that has a NPTY to NATA mutation 12 ), into TAG1 -/-NPCs. In contrast to AICD59, AICD59* could not reverse the abnormal enhancement of neurogenesis in TAG1 -/-NPCs (Fig. 7f, g ). Together, the observations that the abnormal enhancement of neurogenesis in the TAG1 -/-NPCs can be reversed either by application of TAG1 (Fig. 5a ) or transfection with AICD59 (Fig. 7f, g ), and that AICD59* abolishes Fe65 binding and transactivation 12 , support the notion that Fe65 acts as a downstream element in the TAG1-APP signalling pathway, which negatively regulates neurogenesis.
DISCUSSION
Using several approaches, including cell adhesion and co-immunoprecipitation, we have shown that TAG1, a member of the F3 family, binds to APP. TAG1 and APP colocalize in the neurogenic niche of the ventricular zone in the developing mouse brain. Similarly to F3-induced NICD activity 4 , TAG1, as a functional ligand of APP, promotes AICD release in a γ-secretase-dependent manner. We showed that endogenous AICD production increases in a concentration-dependent manner in MEFs that have either been transfected with or treated with TAG1, whereas endogenous AICD production is reduced in embryonic TAG1-null mouse brains when compared with wild-type mice. Concentrationdependent increases in CTF-α and CTF-β in response to TAG1 were also observed in vitro. The increase in neurogenesis seen in neural stem cells isolated from TAG1-null mice was reversed by expression of AICD, confirming that negative modulation of neurogenesis is a physiological function of cleaved AICD. We further demonstrated that the TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. These findings are important in the context of Alzheimer's disease as abnormal processing of APP may also lead to aberrant AICD generation, which may be linked to abnormal intracellular signalling. Further research is required to understand the details of the mechanisms by which the TAG1-APP signalling pathway, as well as its downstream elements, modulate neural stem cells. Knowledge of these mechanisms may provide insights into the cellular processes of neurodegenerative disease and may also offer unique opportunities for pharmacological intervention. A soluble form of TAG1-Fc recombinant protein was produced in 293T cells. The signal sequence of the GPI-anchor of mouse TAG1 was substituted with human IgG-Fc followed by a termination codon. The recombinant cDNA was inserted at the HindIII-NotI sites of pDX, a modified pcDNA3 vector with an amplification-promoting sequence (APS) 15 upstream of the CMV site. The vector was introduced into 293T cells. Fc proteins were purified with the Fc-tag using Protein-A column chromatography, as has been described previously 14 .
The sequences for the Ig and FNIII domains of TAG1 were inserted into the pGEX-KG vector to produce the GST-tagged fusion proteins. The recombinant vectors were introduced into the TOP10 strain of Escherichia coli, which was subsequently induced by IPTG (Bio-Rad Laboratories). The recombinant GST fusion proteins were purified using GST beads (Sigma-Aldrich), according to the manufacturer's instructions.
Cell adhesion assay. CHO cells stably transfected with mouse APP 695 or transiently transfected with APP, F3, TAX, TAG1
or mock cDNA, were cultured in DMEM containing 10% fetal calf serum. The cells were plated on dishes coated with methanol-solubilized nitrocellulose and then with proteins (12 μM). Blockade of adhesion was carried out using polyclonal anti-TAG1 (1:100) or anti-APP (1:100) antibodies. See the Supplementary Information for details. Cells adhering to the various protein spots were photographed and counted. The results were analysed by Newman-Keuls test with P < 0.05 considered significant.
GST or Fc pull-down assays.
Freshly prepared cerebral hemispheres of adult rats were harvested and solubilized in 2% Triton X-100. The buffer homogenate was centrifuged at 13,000g for 1 h at 4 °C and the supernatant was incubated for 45 min at room temperature with glutathione-agarose or protein A-coupled agarose beads that had been incubated with TAG1-Fc or APP-Fc. After washing the beads, proteins were eluted with SDS-PAGE sample buffer and immunoblotted with anti-APP or anti-TAG1 antibodies.
Co-immunoprecipitation.
Mouse brains and NPCs were lysed with RIPA buffer containing a protease inhibitor cocktail (Roche). For immunoprecipitation, lysates were precleared with protein A-coupled agarose beads for 1 h and incubated with APP or TAG1 antibodies together with protein A-coupled agarose overnight at 4 °C. Samples were washed with washing buffer before the beads were re-suspended in SDS buffer and boiled for 3-5 min. Samples were subjected to SDS-PAGE. Western blot analysis was performed and developed with ECL reagents (Amersham Biosciences).
Immunocytochemistry and quantification.
Immunostaining of cultured cells and tissue sections was performed as described previously 15 . Photomicrographs were taken and cells were counted systematically. Each experiment was repeated on 3-7 mice. For details of quantification of immunofluorescence microscopy, see the Supplementary Information. Culture of neural progenitor cells. Telencephalic lateral ventricle walls isolated from E14 embryos were dissociated and neurosphere-forming cells were cultured in DMEM-F12 (Gibco) containing N2 supplement, 20 ng ml -1 bFGF and 20 ng ml -1 EGF. For differentiation assay, second passage neurospheres were collected and dissociated into single cells. The cell suspension was seeded into 24-well dishes with 20,000 cells per well and was induced in DMEM-F12 culture medium containing N2 and 0.5% fetal calf serum for 7-8 days. Nucleofeto II (Amaxa Biosystems) was used for plasmid transfection into NPCs. TUNEL assay. TUNEL assay was performed according to the manufacturer's protocol (Chemicon).
Luciferase assay. The APP-Gal4 assay system has been described previously 7 . CHOL1, CHOTAG1, CHOTAX and non-transfected CHO cells were co-transfected with (1) pG5E1B-luc (Gal4 reporter plasmid); (2) pCMV-LacZ (β-galactosidase control plasmid); (3) pMstAPP (Gal4) or pMstC99 (Gal4); and (4) pCMV5-Fe65 (Fe65) in 24-well dishes. Cells likewise cultured in 24-well dishes were used for AICD-Gal4, C99-Gal4, APP*-Gal4 (with NPTY to NATA mutation), AICD59*-Gal4 (with NPTY to NATA mutation) and Fe65-Gal4 luciferase reporter assays. For the transactivation assay in NPCs, wells were coated with L1-Fc, TAG1-Fc, F3-Fc or laminin protein (8 nM). To examine the role of γ-secretase in this transactivation, different concentrations of γ-secretase inhibitors (L-685,458: 2 or 4 μM; DAPT: 10, 20, 30 or 40 μM; Calbiochem) were applied. Cells were lysed at 24 h after transfection and assayed using the Steady-Glo Luciferase Assay Kit (Promega). The Hes1 luciferase reporter assay has been described previously 4 . See the Supplementary Information for details.
Western blotting for AICD detection in CHO and MEFs, and E15 mouse brain.
Protein extraction for detection of AICD in cell lines was performed as described previously 18, 19 . The protein was loaded onto 16% SDS-Tricine polyacrylamide gel and transferred onto PVDF membranes. Protein extraction to detect AICD in mouse brain was performed as described previously 20 . The protein was applied to 12% SDS-Tricine polyacrylamide gels and transferred onto PVDF membranes. The PVDF membranes were processed for incubation with primary antibodies against the C-terminal of APP (A8717), TAG1 (TG1) and γ-tubulin and detection with ECL Plus or ECL Advance Western Blotting Detection Reagents (Amersham Biosciences). See the Supplementary Information for details.
Cloning of AICD59 and C99. The fragment of AICDC59 was obtained by PCR amplification of the indicated coding sequence of human APP cDNA using the primers: 5´-GGCGTCTAGAGCCACC ATGATAGCGACAGTGATCGTCAT CACC-3(and 5´-GGCGGCGGCCGCCTA GTTCTGCATCTGCTCAAAGA-3. The initial methionine (underlined) was artificially introduced. The product was digested with XbaI and NotI and subcloned into the XbaI-NotI site of pCDF1-MCS1-EF1-copGFP (System Biosciences). The construct was confirmed by sequencing and western blotting (Fig. 5d) . The fragment of Gal4-C99 was obtained by PCR amplification from plasmid pMstAPP (Gal4) using the primers: 5´-GCGC TCTAGA GCCACC ATGGATGCAGAATTCCGACATG -3´ and 5´-GGCGGCGGCCGCCTA GTTCTGCATCTGCTCAAAGA-3. The product was digested with XbaI and NotI and subcloned into the XbaI-NotI site of pCDF-MCS1-EF1-copGFP. The construct was confirmed by sequencing. transfected CHO cells were transiently co-transfected in 24-well culture dishes with pG5E1B plasmid, APP-Gal4-responsive luciferase reporter gene, Fe65 plasmid, and luciferase internal control plasmid or pcDNA3.1-lacZ-myc. After normalization to internal control (a), whole-cell lysates were subjected to SDS PAGEs and Western blots using antibodies against TAG1 (TG1), APP (22C11), Fe65 (3H6), and Gal4 (630403). Normalization to LacZ-myc, another loading control that was detected by antibodies against myc, is presented in c. a and b present two individual experiments. d. Hes1 luciferase reporter activity was affected by neither TAG1 nor F3. NICD transcriptional activity is not triggered by TAG1.
CHO cells were transiently co-transfected in 24-well culture dishes with pGVB-Hes1 luciferase reporter plasmid, luciferase internal control plasmid and TAG1 cDNA, F3 cDNA or NICD cDNA as well as empty vector as a control (Mock). Normalized luciferase activities in whole-cell lysates were determined in triplicate and expressed relative to activity in lysates prepared from mock-transfected CHO cells. e. There were also no detectable differences between the brains of TAG1 +/+ and TAG1 -/-mice in Western blot analysis of the expression levels of NICD of Notch1 and Notch2, Hes1 and Hes5. Brain lysates of TAG1 +/+ (WT) and TAG1 -/-(KO) mice were Western blotted using antibodies against TAG1 (TG1), Notch1 NICD (N1ICD, ab8925), Notch2 NICD (N2ICD, ab8926), Hes1 (AB5702), Hes5 (ab25374) and γ-Tubulin.
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In all the graphs, the error bars indicate standard error of the mean (SEM). *: P<0.05; **:
P<0.001.
Luciferase assay
The APP-Gal4 assay system has been previously described 
Western blotting for AICD detection in CHO and MEF cells and E15 mouse brain
Protein extraction for detection of AICD in cell lines was as previously described 18, 19 (in text) . Protein extraction to detect AICD in mouse brain was as previously described 20 (in text) . Briefly, E15 mice brains were homogenized and sonicated in buffer (20mM HEPESNaOH (pH 7.4), 150 mM NaCl, 10% glycerol, 5 mM EDTA, 20 mM NH4Cl) containing 0.5% TritonX-100, 5mg/ml chymostatin, and 5mg/ml leupeptin, and incubated on ice for 
SUPPLEMENTARY DISCUSSION
We first showed that TAG1 and APP bind to each other in cell adhesion assays using a system in which the proteins were overexpressed in CHO cells. We also investigated However, the transcriptional activity of the AICD product cleaved from APP has been controversial. It was reported that binding to Fe65 stabilizes AICD and that both Fe65 and AICD translocate to the nucleus 11 . AICD appeared to have transcriptional activity in complex with Fe65 and histone acetyltransferase Tip60
(in text)
. However, this transcriptional activity was in the same artificial reporter gene assay that we used in the present study. This artificial reporter assay system can detect release of AICD tagged with Gal4 but, as the response element is Gal4, activity in this system does not reflect endogenous transcriptional activity of AICD. Whether AICD is involved in endogenous transcriptional activation remains to be further investigated. Moreover, the role of AICD in the mechanisms of the transcriptional activation has also been controversial. Early evidence suggested that Fe65 bound to APP and that when AICD was cleaved the two proteins translocated to the nucleus together 7 (in text), 11 complexing with Tip60
.
Later evidence indicated that membrane-tethered AICD recruits and activates Fe65 allowing its translocation to the nucleus but that it is not essential for Fe65-dependent transcriptional transactivation 12 (in text) . Moreover, a subsequent study confirmed that Fe65 alone was sufficient for transcriptional transactivation and that APP and Tip60 play positive and negative modulatory roles, respectively 12 . Investigation of the phosphorylation of APP at Thr688 (residue numbering for the APP695 form), which reduces or prevents Fe65 binding to APP 13 and disrupts the stabilization of AICD by , although the transcriptional control of KAI1, GSK-3 , APP and neprilysin have been controversial [21] [22] [23] . In the case of the epidermal growth factor receptor (EGFR), direct binding of endogenous AICD to the EGFR promoter is reported 20 . It has also been suggested that AICD can enhance the transcriptional activation of another transcription factor, p53 24 . Thus, despite the controversy over whether AICD is itself a transcription factor in the AICD-Fe65-Tip60 system, there is growing evidence that AICD can influence gene transcription. It is therefore of interest to understand the regulation of AICD cleavage. Our finding that TAG1 can stimulate AICD-dependent activity in a -secretase dependent manner in the artificial luciferase reporter system is evidence that TAG1 can act as a functional ligand for APP. . Although A and AICD production do not appear to be tightly linked 26 , altered APP processing may influence AICD production or lead to formation of alterative C-terminal products 27 , which could have implications for physiological signaling via the AICD-dependent TAG1-APP signaling pathway. TAG1 did appear to increase both production of both CTF-and CTF-. It would however be overly speculative at this stage to draw parallels between our finding that TAG1-APP signaling negatively modulates neurogenesis in NPCs isolated from the fetal mouse cortex and the reported increase in neurogenesis in an AD mouse model 28 and the adult human hippocampus in AD 29 . Not only do the mechanisms regulating neurogenesis differ between fetal and adult brain and between hippocampus and cortex, but also the changes in neurogenesis in AD and their implications are controversial 30 .
In summary, we have shown that TAG1, a member of the F3 family, is a functional ligand of APP. Similar to F3 triggered NICD activity 4 (in text) , this ligand binding promotes AICD release in a -secretase-dependent manner. Moreover, we have demonstrated that the TAG1-APP signaling pathway through Fe65 negatively modulates neurogenesis. Importantly, the increase in neurogenesis observed in neural stem cells isolated from TAG1 null mice was reversed by expression of AICD, confirming that negative modulation of neurogenesis is a physiological role of cleaved AICD. These findings are important in the context of Alzheimer's disease because abnormal processing of APP could also lead to aberrant AICD generation, which may be linked to abnormal intracellular signaling. Further research is required to understand the details of the mechanisms by which the TAG1-APP signaling pathway as well as its downstream elements modulate neural stem cells. Knowledge of these mechanisms will provide insights into the cellular processes of neurodegenerative disease and may also offer unique opportunities for pharmacological intervention.
